This biotech has candidates in late-stage clinical development.

Both ANI Pharmaceuticals ANIP and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on generic and ...

Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on ...

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.

Veeva Systems markets a suite of software services geared toward the biopharmaceutical industry. A wholly owned customer relationship management service is gaining steam for Veeva Systems. With access ...

Roth's $212 price target implies an additional upside of 32% for shares of Insmed, which have already rallied 160% in the last 12 months.

Swiss bank UBS reports that the White House may reach a deal with GLP-1 weight loss drug producers Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) to adjust their pricing lower for U.S. customers.

Journey Medical (DERM): microcap biopharma with cash-generating dermatology portfolio and high-upside Emrosi launch. Read ...

Pfizer has a substantial 6.6% dividend yield but a payout ratio exceeding 100%. Eli Lilly has a payout ratio of roughly 30%, but its dividend yield is a tiny 0.6%. Long-term income investors can find ...

Pfizer currently has a 7% yield, and the company is making important business moves. Bristol Myers Squibb has a 5.6% yield and has been building its drug pipeline with acquisitions. Merck has a 3.7% ...

The drug discovery company, which also invests in solar energy assets, revealed that its wholly-owned subsidiary MitoCareX ...